Elicio Therapeutics’ ELI-002 7P shows antigen spreading in Phase 2 trial

Elicio Therapeutics (ELTX) announced that analysis of a subset of patients in the ongoing Phase 2 AMPLIFY-7P trial has demonstrated that a majority of evaluated patients – 13 out of 15 – treated with ELI-002 7P induced antigen spreading targeting non-mKRAS neoantigens that are not present in the ELI-002 7P targeted immunotherapy. Consistent with prior observations in Phase 1, treatment with ELI-002 7P in these evaluated patients resulted in T cell responses targeting personalized tumor antigens in addition to responses directed at the driver mKRAS antigens included in the therapy. Antigen spreading refers to the expansion of the immune response from the initial target antigen to new secondary tumor-specific antigens. The broader multi-targeted immunity which results from antigen spreading may limit the potential for tumors to evade immune responses, leading to more durable responses. 87% of evaluated patients demonstrated significant expansion of T cells specific for non-mKRAS tumor neoantigens. The induction of broad T cell responses targeting mKRAS, alongside other personalized tumor antigens, may contribute to more robust anti-tumor immunity, including the potential to prevent relapse.